Latest diazepam Stories

Diazepam Addiction Treatment and Drug Rehab Announced by Recovery Associates, Offering Treatment for Those Addicted to Diazepam. WEST PALM BEACH, Fla. (PRWEB) May 21, 2013 Recovery Associates, through its multiple therapeutic tracks, is placing an emphasis upon Diazepam addiction treatment, helping men and women stop using and break free from this harrowing drug. Diazepam is used to treat muscle spasms, anxiety disorder, and seizures. It is also prescribed to control agitation brought on...

Freedom Treatment Center is a drug and alcohol addiction recovery facility that is ramping up efforts to reach out and help people recognize the signs of drug abuse and addiction before it’s too late. The Southern Michigan recovery facility offers natural methods of detoxification that can help halt the continuous increase in drug overdose deaths every year in the U.S. Albion, MI (PRWEB) March 01, 2013 With drug overdose deaths in the U.S. on the increase for the 11th year in a row,...

Benzodiazepines affect immune system; Further scrutiny of safety warranted Commonly prescribed sleeping pills/sedatives may increase the risk of contracting pneumonia by as much as 50% and increase the risk of dying from it, suggests research published online in the journal Thorax. Benzodiazepines have a wide range of uses and are commonly prescribed for anxiety, epilepsy, muscle spasm, and insomnia. They are also frequently used in palliative care, as a sedative, and to help those with...

Lee Rannals for redOrbit.com – Your Universe Online Researchers are warning that taking sleeping pills may significantly increase your risk of developing dementia later in life. A Harvard University study found that those who used benzodiazepines were 50% more likely to succumb to the condition. During the study, researchers involved 1,063 men and women over the age of 65 for a period of 20 years in southwest France. At the onset of the study, none of the participants had...

INDIANAPOLIS, June 27, 2012 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch in the U.S. and Canada of the cobas p 312 pre-analytical system, a front-end automation solution that offers comprehensive, vendor-neutral sample management for labs with limited floor space. The compact, stand-alone system performs sample registration, sorting, decapping and archiving of all sample tubes--including chemistry, immunoassay, hematology, coagulation and...

PENZBERG, Germany, March 28, 2012 /PRNewswire/ -- Roche's xCELLigence RTCA [https://www.roche-applied-science.com/sis/xcelligence/index.jsp?&id=xcect_000000 ] System is being used in the European Union's SEURAT (Safety Evaluation Ultimately Replacing Animal Testing) initiative to run five years from 2011 to 2016. As of 2013, animal experiments are no longer permitted for use in toxicology testing in the cosmetic industry. Significant progress has been made in recent years...

SAN DIEGO, Feb. 6, 2012 /PRNewswire/ -- Neurelis, Inc. today announced that the United States Food and Drug Administration (FDA) has cleared an Investigational New Drug application (IND) to commence clinical trials advancing the development of NRL-1 for the treatment of acute breakthrough seizures. Following initial pre-IND discussions with FDA in late 2011, Neurelis filed the IND based upon the encouraging human pharmacokinetic results seen when comparing absolute...

New Therapy Grants Program Supports Four Innovative Approaches to Treat or Detect Epilepsy Next Grant Award Application Cycle is Now Open WASHINGTON, Dec. 6, 2011 /PRNewswire-USNewswire/ -- The Epilepsy Therapy Project (ETP) and the Epilepsy Foundation (EF) today announced the latest grant recipients of their New Therapy Grants Program, a unique joint venture of the two non-profit epilepsy organizations to advance clinical development and commercialization of promising...

BASEL, Switzerland and NUTLEY, N.J., Sept. 9, 2011 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the initiation of its first Phase 1 clinical trial to investigate the safety and tolerability of a molecule designed to address the cognitive and behavioral deficits associated with Down syndrome. "There is currently a large unmet medical need for the treatment of cognitive impairments in individuals suffering from Down syndrome," comments Luca Santarelli, Global Head of...

EXTON, Pa., Sept. 6, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the European Commission has granted a Centralized Pediatric Use Marketing Authorization (PUMA) for Buccolam® (midazolam, oromucosal solution), for treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents, from 3 months to less than 18 years of age. This action by the European Commission represents the first product approval through the...